Total emitted dose of salbutamol sulphate at different inhalation flows and inhalation volumes through different types of dry powder inhalers

Boshra, Marian S.; Almeldien, Ahmed G; Eldin, Randa Salah; Elberry, Ahmed A.; Abdelwahab, Nada S.; Salem, Mohamed; Rabea, Hoda; Abdelrahim, Mohamed

doi:10.1080/01902148.2018.1489015

Cited by 12 publications

(15 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The codes for the in vitro model included; X1: Dry powder inhaler type [0.1 for Turbohaler (Terbutaline); 0.2 for Diskus (Salbutamol) and 0.3 for the Aerolizer (formoterol fumarate)] as shown in Table 1, X2: Inhalation flow (10, 20, 30, 40, 50 and 60 L/min), X3: Inhalation volume (2 and 4 L) and X4: Number of inhalations (1 or 2). The output property Y1 is the percentage of the emitted dose, respectively 6,18 …”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

In vitro and in vivo performance modelling and optimisation of different dry powder inhalers: A complementary study of neural networks, genetic algorithms and decision trees

et al. 2020

Self Cite

View full text Add to dashboard Cite

Introduction Aerosol delivery from DPIs could be affected by different factors. This study aimed to evaluate and predict the effects of different factors on drug delivery from DPIs. Methods Modelling and optimisation for both in vitro and in vivo data of different DPIs (Diskus, Turbohaler and Aerolizer) were carried out using neural networks associated with genetic algorithms and the results are confirmed using a decision tree (DT) and random forest regressor (RFR). All variables (the type of DPI, inhalation flow, inhalation volume, number of inhalations and type of subject) were coded as numbers before using them in the modelling study. Results The analysis of the in vitro model showed that Turbohaler had the highest emitted dose compared with the Diskus and the Aerolizer. Increasing flow resulted in a gradual increase in the emitted dose. Little differences between the inhalation volumes 2 and 4 litres were shown at fast inhalation flow, and interestingly two inhalations showed somewhat higher emitted doses than one‐inhalation mode with Turbohaler and Diskus at slow inhalation flow. Regarding the in vivo model, the percent of drug delivered to the lung was highly increased with Turbohaler and Diskus in healthy subjects where continuous contour lines were observed. The Turbohaler showed increased lung bioavailability with the two‐inhalation modes, the Diskus showed a nearly constant level at both one and two inhalations at slow inhalation. The Turbohaler and Aerolizer showed little increasing effect moving from one to two inhalations at slow inhalation. Conclusions Modelling of the input data showed a good differentiating and prediction power for both in vitro and in vivo models. The results of the modelling refer to the high efficacy of Diskus followed by Turbohaler for delivering aerosol. With two inhalations, the three DPIs showed an increase in the percent of drug excreted at slow inhalations.

show abstract

Section: Methodsmentioning

confidence: 99%

“…The optimum inhalation volume for the best aerosol delivery should be determined for each DPI. Guidelines for using different DPIs are available for optimising the emitted potion of aerosol 17,18 . Hence, DPI efficiency is highly dependent on the patient's inspiratory effort, formulation characteristics and inhalation technique.…”

Section: Introductionmentioning

confidence: 99%

In vitro and in vivo performance modelling and optimisation of different dry powder inhalers: A complementary study of neural networks, genetic algorithms and decision trees

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Concerning RIF determination, data generating from each animal in terms of drug concentration were related to the drug loading corresponding to each administered sample. Moreover, since relationships between dosage emission and device flow-rate are well known [33][34][35], the actual inhaled dose per mouse was calculated by considering RIF amount not emitted by the device. The actual emission doses were ≥70% of those loaded inside the device (78.6 ± 3.3%, 69.3 ± 9.2%, 85.6 ± 5.4%, for SLNas/MS, SLNas/MS-ST, SLNas/ST, respectively) apart from SLNas/F127 with an emission dose of 53.4 ± 10.7% owing to its very poor flowability and high cohesiveness already highlighted in our previous work [17].…”

Section: In Vivo Studymentioning

confidence: 99%

In Vivo Biodistribution of Respirable Solid Lipid Nanoparticles Surface-Decorated with a Mannose-Based Surfactant: A Promising Tool for Pulmonary Tuberculosis Treatment?

et al. 2020

View full text Add to dashboard Cite

The active targeting to alveolar macrophages (AM) is an attractive strategy to improve the therapeutic efficacy of ‘old’ drugs currently used in clinical practice for the treatment of pulmonary tuberculosis. Previous studies highlighted the ability of respirable solid lipid nanoparticle assemblies (SLNas), loaded with rifampicin (RIF) and functionalized with a novel synthesized mannose-based surfactant (MS), both alone and in a blend with sodium taurocholate, to efficiently target the AM via mannose receptor-mediated mechanism. Here, we present the in vivo biodistribution of these mannosylated SLNas, in comparison with the behavior of both non-functionalized SLNas and bare RIF. SLNas biodistribution was assessed, after intratracheal instillation in mice, by whole-body real-time fluorescence imaging in living animals and RIF quantification in excised organs and plasma. Additionally, SLNas cell uptake was determined by using fluorescence microscopy on AM from bronchoalveolar lavage fluid and alveolar epithelium from lung dissections. Finally, histopathological evaluation was performed on lungs 24 h after administration. SLNas functionalized with MS alone generated the highest retention in lungs associated with a poor spreading in extra-pulmonary regions. This effect could be probably due to a greater AM phagocytosis with respect to SLNas devoid of mannose on their surface. The results obtained pointed out the unique ability of the nanoparticle surface decoration to provide a potential more efficient treatment restricted to the lungs where the primary tuberculosis infection is located.

show abstract

“…Our data showed that after two inhalations, the theophylline dose emitted was 90% and 91% from Breezhaler® and Handihaler® respectively, this suggests that our data was in line with the optimised models described by Ali and Abdelrahim. Boshra et al, (2018) compared the performance of two inhaler devices namely Diskus® and Aeroliser® using two separate inhalations. Their results showed that at an inhalation flow ≤30 L min −1 two inhalations resulted in higher TED than one inhalation.…”

Section: Resultsmentioning

confidence: 99%

The effect of inspiratory parameters after two separate inhalations on the dose emission of theophylline from low and high resistance dry powder inhalers

Abadelah

Al-Assadi

Rooney

et al. 2020

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

show abstract

Total emitted dose of salbutamol sulphate at different inhalation flows and inhalation volumes through different types of dry powder inhalers

Cited by 12 publications

References 21 publications

In vitro and in vivo performance modelling and optimisation of different dry powder inhalers: A complementary study of neural networks, genetic algorithms and decision trees

In vitro and in vivo performance modelling and optimisation of different dry powder inhalers: A complementary study of neural networks, genetic algorithms and decision trees

In Vivo Biodistribution of Respirable Solid Lipid Nanoparticles Surface-Decorated with a Mannose-Based Surfactant: A Promising Tool for Pulmonary Tuberculosis Treatment?

The effect of inspiratory parameters after two separate inhalations on the dose emission of theophylline from low and high resistance dry powder inhalers

Contact Info

Product

Resources

About